SalubrisBio parent company Salubris Pharmaceuticals announces investment of $10M in Viracta Therapeutics (San Diego, USA) to support development of their kick-and-kill combination cancer therapy
By: jonadmin|Published on: Oct 27, 2020|Categories: |
Recent Posts
- Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress
- Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates
- Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction
- Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer
- Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases
Recent Comments